July 25, 2017 2:11 PM ET


Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The company’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating...

1880 Century Park East

Suite 1000

Los Angeles, CA 90067

United States

Founded in 2004

7 Employees





Key Executives for Ritter Pharmaceuticals, Inc.

CEO & Director
Age: 57
Total Annual Compensation: $376.3K
Co-Founder, President, Corporate Secretary & Director
Age: 34
Total Annual Compensation: $441.2K
Co-Founder, Executive Chairman & Chief Strategic Officer
Age: 68
Total Annual Compensation: $405.9K
Compensation as of Fiscal Year 2016.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

On June 7, 2017, Ritter Pharmaceuticals, Inc. received a letter (Notice) from The Nasdaq Stock Market (Nasdaq) notifying the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the common stock on The Nasdaq Capital Market. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until December 4, 2017 to regain compliance with the Minimum Bid Price Requirement. During the compliance period, the Company’s shares of common stock will continue to be listed and traded on The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. In the event the Company is not in compliance with the Minimum Bid Price Requirement by December 4, 2017 the Company may be afforded a second 180 calendar day grace period. To qualify, the Company would be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. In addition, the Company would be required to provide written notice of its intention to cure the minimum bid price deficiency during this second 180 day compliance period by effecting a reverse stock split, if necessary. The Company intends to actively monitor the bid price for its common stock between now and December 4, 2017 and will consider available options to regain compliance with the Minimum Bid Price Requirement.

Ritter Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2017

Ritter Pharmaceuticals, Inc. announced unaudited earnings results for the first quarter ended March 31, 2017. For the period, the company's operating loss was $1,681,181 compared to $3,150,230 a year ago. The company reported a net loss attributable to common stockholders of approximately $1.7 million compared to a net loss of approximately $3.1 million for the first quarter of 2016. Basic and diluted net loss per share was $0.14 for the three months ended March 31, 2017 compared to basic and diluted net loss per share of $0.36 for the same period in 2016.

Ritter Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2017

Ritter Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2017, at 09:00 Pacific Standard Time. Location: 1901 Avenue of the Stars, Suite 700 Los Angeles, CA 90067-6078 United States Agenda: To elect as directors the eight nominees; to ratify the appointment of Mayer Hoffman McCann P.C., as independent registered public accounting firm for the fiscal year ending December 31, 2017; to approve the amendment of the company's 2015 Equity Incentive Plan, in substantially the form of Annex A to this proxy statement, to increase the number of shares that may be issued pursuant to awards thereunder by 838,000 shares to an aggregate of (i) 1,641,289 shares plus (ii) any shares that were available for grant under the 2008 Stock Plan and the 2009 Stock Plan on the effective date of the 2015 Equity Incentive Plan or were subject to awards under the Prior Plans that, after the effective date of the 2015 Equity Incentive Plan, were or are forfeited or lapse unexercised or were or are settled in cash and are not issued under the Prior Plans.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ritter Pharmaceuticals, Inc., please visit www.ritterpharmaceuticals.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.